LBF18110HP01: Difference between revisions
No edit summary |
No edit summary |
||
(13 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
{{Lipid/Header}} | |||
{{Hierarchy|{{PAGENAME}}}} | {{Hierarchy|{{PAGENAME}}}} | ||
Line 4: | Line 6: | ||
|LipidBank=DFA8068 | |LipidBank=DFA8068 | ||
|LipidMaps=LMFA01040052 | |LipidMaps=LMFA01040052 | ||
|SysName=Methyl-10,12,13,15- | |SysName=Methyl-10,12,13,15-bisepidioxy-16-hydroperoxy-8-octadecenoic acid | ||
|Common Name=&&Methyl-10,12,13,15- | |Common Name=&&Methyl-10,12,13,15-bisepidioxy-16-hydroperoxy-8-octadecenoate&& | ||
|Mass Spectra=GC-EI-MS(after reduction(PH3P) and TMS-derivatization)(105): m/e=313[M-131]; 131[SMTO=CHCH2CH3]; GC-EI-MS(after reduction,hydrogenation, and TMS-derivatization)[[Reference:Neff_WE:Frankel_EN:Weisleder_D:,Lipids,1982,17,780|{{RelationTable/GetFirstAuthor|Reference:Neff_WE:Frankel_EN:Weisleder_D:,Lipids,1982,17,780}}]]: m/e=349[SMTO=CHCH2CH(OTMS)CH(OTMS)CH2CH3]; 273[SMTO=CH(CH2)8COOCH3] | |Mass Spectra=GC-EI-MS(after reduction(PH3P) and TMS-derivatization)(105): m/e=313[M-131]; 131[SMTO=CHCH2CH3]; GC-EI-MS(after reduction,hydrogenation, and TMS-derivatization)[[Reference:Neff_WE:Frankel_EN:Weisleder_D:,Lipids,1982,17,780|{{RelationTable/GetFirstAuthor|Reference:Neff_WE:Frankel_EN:Weisleder_D:,Lipids,1982,17,780}}]]: m/e=349[SMTO=CHCH2CH(OTMS)CH(OTMS)CH2CH3]; 273[SMTO=CH(CH2)8COOCH3] | ||
|IR Spectra=OOH group: 3700-3150cm | |IR Spectra=OOH group: 3700-3150cm^{-1}[bonded], 3530cm^{-1}[free]; isolated trans unsaturation: 960cm^{-1}[[Reference:Neff_WE:Frankel_EN:Weisleder_D:,Lipids,1982,17,780|{{RelationTable/GetFirstAuthor|Reference:Neff_WE:Frankel_EN:Weisleder_D:,Lipids,1982,17,780}}]] | ||
|NMR Spectra= | |NMR Spectra=^1 H-NMR[[Reference:Neff_WE:Frankel_EN:Weisleder_D:,Lipids,1982,17,780|{{RelationTable/GetFirstAuthor|Reference:Neff_WE:Frankel_EN:Weisleder_D:,Lipids,1982,17,780}}]]: C2: 2.3ppm; C8: 5.35ppm; C9: 5.88ppm; C10, 12, 13, 15: 4.47ppm; C11, 14: 2.1-2.8ppm; C16: 3.88ppm[C15-16 erythro], 4.17ppm[C15-16 threo]; C18: 1.05ppm; OOH: 8.73ppm[C15-16 erythro], 9.20ppm[C15-16 threo] [[Reference:Neff_WE:Frankel_EN:Weisleder_D:,Lipids,1982,17,780|{{RelationTable/GetFirstAuthor|Reference:Neff_WE:Frankel_EN:Weisleder_D:,Lipids,1982,17,780}}]] | ||
|Source=It is produced from a 10-peroxyradical by singlet-oxygen mediated oxidation of linoleate via succesive 1,3-cyclization[[Reference:Frankel_EN:,Prog. Lipid Res.,1984,23,197|{{RelationTable/GetFirstAuthor|Reference:Frankel_EN:,Prog. Lipid Res.,1984,23,197}}]][[Reference:Frankel_EN:,Chem. Phys. Lipids,1987,44,73|{{RelationTable/GetFirstAuthor|Reference:Frankel_EN:,Chem. Phys. Lipids,1987,44,73}}]][[Reference:Neff_WE:Frankel_EN:Weisleder_D:,Lipids,1982,17,780|{{RelationTable/GetFirstAuthor|Reference:Neff_WE:Frankel_EN:Weisleder_D:,Lipids,1982,17,780}}]]. | |||
|Chemical Synthesis= | |||
|Metabolism= | |||
|Biological Activity=It reacts with DNA in the presence of Fe ions and ascorbic acid[[Reference:Fujimoto_K:Neff_WE:Frankel_EN:,Biochim. Biophys. Acta,1984,795,100|{{RelationTable/GetFirstAuthor|Reference:Fujimoto_K:Neff_WE:Frankel_EN:,Biochim. Biophys. Acta,1984,795,100}}]]. | |||
}} | }} | ||
{{Lipid/Footer}} |
Latest revision as of 21:00, 14 April 2010
LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
IDs and Links | |
---|---|
LipidBank | DFA8068 |
LipidMaps | LMFA01040052 |
CAS | |
KEGG | {{{KEGG}}} |
KNApSAcK | {{{KNApSAcK}}} |
mol | LBF18110HP01 |
Methyl-10,12,13,15-bisepidioxy-16-hydroperoxy-8-octadecenoate | |
---|---|
Structural Information | |
Methyl-10,12,13,15-bisepidioxy-16-hydroperoxy-8-octadecenoic acid | |
| |
Formula | C19H32O8 |
Exact Mass | 388.20971799999995 |
Average Mass | 388.45258 |
SMILES | C(O1)(C(CC)OO)CC(C(O2)CC(C=CCCCCCCC(=O)OC)O2)O1 |
Physicochemical Information | |
It is produced from a 10-peroxyradical by singlet-oxygen mediated oxidation of linoleate via succesive 1,3-cyclization Frankel_EN Frankel_EN Neff_WE et al.. | |
It reacts with DNA in the presence of Fe ions and ascorbic acid Fujimoto_K et al.. | |
Spectral Information | |
Mass Spectra | GC-EI-MS(after reduction(PH3P) and TMS-derivatization)(105): m/e=313[M-131]; 131[SMTO=CHCH2CH3]; GC-EI-MS(after reduction,hydrogenation, and TMS-derivatization) Neff_WE et al.: m/e=349[SMTO=CHCH2CH(OTMS)CH(OTMS)CH2CH3]; 273[SMTO=CH(CH2)8COOCH3] |
UV Spectra | |
IR Spectra | OOH group: 3700-3150cm-1[bonded], 3530cm-1[free]; isolated trans unsaturation: 960cm-1 Neff_WE et al. |
NMR Spectra | 1H-NMR Neff_WE et al.: C2: 2.3ppm; C8: 5.35ppm; C9: 5.88ppm; C10, 12, 13, 15: 4.47ppm; C11, 14: 2.1-2.8ppm; C16: 3.88ppm[C15-16 erythro], 4.17ppm[C15-16 threo]; C18: 1.05ppm; OOH: 8.73ppm[C15-16 erythro], 9.20ppm[C15-16 threo] Neff_WE et al. |
Other Spectra | |
Chromatograms |
Reported Metabolites, References | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|